{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:56:00Z","timestamp":1790751360353,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2021xkj237"],"award-info":[{"award-number":["2021xkj237"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Chromobox protein homolog 3 (CBX3) has been recognized as a member of the heterochromatin protein 1 family and participate in transcriptional activation or inhibition, cell differentiation and growth. Despite more and more evidence shows that CBX3 has a critical function in the development of some tumors, no systematic extensive analysis of CBX3 has been reported. Thus, we intended to examine the prognostic significance of CBX3 in 33 tumors and investigate its potential immune function. We employed several bioinformatics methods to explore the potential carcinogenic impact of CBX3 premised on the data sets collected from tumor genome maps, human protein maps, cBioPortal, and genotype tissue expression. The approaches include assessing the link between CBX3 and prognosis of different tumors, immune cell infiltration, micro-satellite instability (MSI), DNA methylation, and tumor mutational burden (TMB). The outcomes illustrated that CBX3 was increasingly expressed in 29 tumors. Moreover, CBX3 exhibited a negative correlation with the prognosis of many tumors. The expression of CBX3 was linked to MSI in 12 tumors and TMB in 16 tumors. In 24 tumors, the expression of CBX3 was linked to DNA methylation. Moreover, the CBX3 expression exhibited a negative relationship with the infiltration level of the majority of immune cells, but showed a positive link to T gamma delta cells, central memory T cells, and T helper cells, especially when invading breast carcinoma, thymic carcinoma, colon carcinoma, cutaneous melanoma, endometrial carcinoma, and lung squamous carcinoma. Our research indicates that CBX3 might be used as a prognostic indicator for different malignant tumors due to its function in tumor genesis as well as tumor immunity.<\/jats:p>","DOI":"10.3389\/fmed.2022.869994","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:54:11Z","timestamp":1651139651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Analysis of Pan-Cancer Revealed the Immunological and Prognostic Potential of CBX3 in Human Tumors"],"prefix":"10.3389","volume":"9","author":[{"given":"Haitao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dangui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"107078","DOI":"10.1016\/j.intimp.2020.107078","article-title":"Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer","volume":"89","author":"Liu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1126\/science.1078572","article-title":"Maintenance of stable heterochromatin domains by dynamic HP1 binding","volume":"299","author":"Cheutin","year":"2003","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1038\/onc.2014.278","article-title":"Homeodomain\u2013interacting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1gamma","volume":"34","author":"Akaike","year":"2015","journal-title":"Oncogene."},{"key":"B6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/35020506","article-title":"Regulation of chromatin structure by site\u2013specific histone H3 methyltransferases","volume":"406","author":"Rea","year":"2000","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1101\/gad.17325211","article-title":"A role for heterochromatin protein 1gamma at human telomeres","volume":"25","author":"Canudas","year":"2011","journal-title":"Genes Dev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e15507","DOI":"10.1371\/journal.pone.0015507","article-title":"Role of the epigenetic regulator HP1gamma in the control of embryonic stem cell properties","volume":"5","author":"Caillier","year":"2010","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2407-13-148","article-title":"HP1gamma expression is elevated in prostate cancer and is superior to gleason score as a predictor of biochemical recurrence after radical prostatectomy","volume":"13","author":"Slezak","year":"2013","journal-title":"BMC cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1158\/0008-5472.CAN-14-3735","article-title":"Heterochromatin protein HP1gamma promotes colorectal cancer progression and is regulated by miR\u221230a","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bbrc.2018.04.137","article-title":"CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer","volume":"500","author":"Chen","year":"2018","journal-title":"Biochem Biophys Res Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41388-021-02114-8","article-title":"Smoking\u2013associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma","volume":"41","author":"Jin","year":"2022","journal-title":"Oncogene."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e41401","DOI":"10.1371\/journal.pone.0041401","article-title":"Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma","volume":"7","author":"Saini","year":"2012","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3892\/etm.2018.5969","article-title":"CBX3\/HP1gamma is upregulated in tongue squamous cell carcinoma and is associated with an unfavorable prognosis","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"92375","DOI":"10.18632\/oncotarget.21325","article-title":"Prognostic values of distinct CBX family members in breast cancer","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget."},{"key":"B16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41417-020-0174-y","article-title":"TMB: a promising immune\u2013response biomarker, and potential spearhead in advancing targeted therapy trials","volume":"27","author":"Choucair","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102024","DOI":"10.1016\/j.ctrv.2020.102024","article-title":"MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma","volume":"86","author":"van Velzen","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS\u2013driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome biology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1200\/JCO.2004.07.151","article-title":"DNA methylation and cancer","volume":"22","author":"Das","year":"2004","journal-title":"Am. J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"596545","DOI":"10.3389\/fonc.2020.596545","article-title":"Association of axillary lymph node evaluation with survival in women aged 70 years or older with breast cancer","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12885-015-1440-5","article-title":"Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival","volume":"15","author":"Pelkonen","year":"2015","journal-title":"BMC cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/annonc\/mdu478","article-title":"Prioritizing targets for precision cancer medicine","volume":"25","author":"Andre","year":"2014","journal-title":"Ann Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12967-019-1930-3","article-title":"Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma","volume":"17","author":"Wang","year":"2019","journal-title":"J Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.2147\/CMAR.S271807","article-title":"CBX3 promotes gastric cancer progression and affects factors related to immunotherapeutic responses","volume":"12","author":"Lin","year":"2020","journal-title":"Cancer Manag Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12920-022-01179-y","article-title":"Comprehensive pan\u2013cancer analysis on CBX3 as a prognostic and immunological biomarker","volume":"15","author":"Niu","year":"2022","journal-title":"BMC Med Genomics."},{"key":"B29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.gene.2018.02.043","article-title":"CBX3 promotes tumor proliferation by regulating G1\/S phase via p21 downregulation and associates with poor prognosis in tongue squamous cell carcinoma","volume":"654","author":"Zhang","year":"2018","journal-title":"Gene."},{"key":"B30","doi-asserted-by":"publisher","first-page":"19934","DOI":"10.18632\/oncotarget.15253","article-title":"CBX3 promotes colon cancer cell proliferation by CDK6 kinase\u2013independent function during cell cycle","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.3892\/mmr.2019.10104","article-title":"CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma","volume":"19","author":"Ma","year":"2019","journal-title":"Mol Med Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/0008-5472.CAN-17-3571","article-title":"HP1gamma promotes lung adenocarcinoma by downregulating the transcription-repressive regulators NCOR2 and ZBTB7A","volume":"78","author":"Alam","year":"2018","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.21037\/jgo-20-208","article-title":"Comprehensive analysis of the prognosis for chromobox family in gastric cancer","volume":"11","author":"Lin","year":"2020","journal-title":"J Gastrointest Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bib\/bbaa424","article-title":"Deciphering the genetic code of DNA methylation","volume":"22","author":"Wang","year":"2021","journal-title":"Brief Bioinform"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/cancers13030545","article-title":"Role of methylation in pro\u2013 and anti\u2013cancer immunity","volume":"13","author":"Mehdi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","article-title":"Tumor mutation burden: leading immunotherapy to the era of precision medicine?","volume":"36","author":"Steuer","year":"2018","journal-title":"Am J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1158\/1078-0432.CCR-19-1105","article-title":"Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","article-title":"Tumor mutation burden as a biomarker in resected non\u2013small\u2013cell lung cancer","volume":"36","author":"Devarakonda","year":"2018","journal-title":"J Clin Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM200001133420201","article-title":"Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer","volume":"342","author":"Gryfe","year":"2000","journal-title":"N Engl J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cells8101140","article-title":"The role of mirnas in immune cell development, immune cell activation, and tumor immunity: with a focus on macrophages and natural killer cells","volume":"8","author":"Xu","year":"2019","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"42888","DOI":"10.1038\/srep42888","article-title":"Cbx3\/HP1gamma deficiency confers enhanced tumor\u2013killing capacity on CD8(+) T cells","volume":"7","author":"Sun","year":"2017","journal-title":"Sci Rep."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.869994\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:54:16Z","timestamp":1651139656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.869994\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":44,"alternative-id":["10.3389\/fmed.2022.869994"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.869994","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"869994"}}